ArticleJournal of controlled release : official journal of the Controlled Release Society2019
Functional assessment of peptide-modified PLGA nanoparticles against oral biofilms in a murine model of periodontitis.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 64 citations in OpenAlex.
- Curcumin-Based Nanoformulations for Oral Health: Mechanistic Insights, Antimicrobial Efficacy, and Future Clinical Perspectives.Biomedicines · 2026Review
- Application and Potential of Local Drug Delivery Systems for Antibacterial Treatment of Periodontitis.International journal of molecular sciences · 2026Review
- Nanoparticle-Based Drug Delivery Systems for Periodontitis: Antibacterial, Immunomodulatory, and Regenerative Strategies.International journal of nanomedicine · 2026Review
- Nanoscale Approaches to Oro-Dental Tissue Engineering: A Review of Strategies, Composites, and Translational Challenges.International journal of nanomedicine · 2026Review
- Nanoparticle-based drug delivery systems for non-surgical periodontal therapy: innovations and clinical applications.3 Biotech · 2025Review
- Advances in Local Drug Delivery for Periodontal Treatment: Present Strategies and Future Directions.Biomolecules · 2025Review
- Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Beyond antibiotics: advances in photothermal strategies for oral infections.Frontiers in bioengineering and biotechnology · 2025Review
- Advancing Nanotechnology: Targeting Biofilm-Forming Bacteria with Antimicrobial Peptides.BME frontiers · 2025Review
- Nanomaterials: innovative approaches for addressing key objectives in periodontitis treatment.RSC advances · 2024Review
- Advances in hybridized nanoarchitectures for improved oro-dental health.Journal of nanobiotechnology · 2024Review
- Effect of Dietary Composite Probiotic Supplementation on the Microbiota of Different Oral Sites in Cats.Veterinary sciences · 2024Article
- 3D printing technology and its combination with nanotechnology in bone tissue engineering.Biomedical engineering letters · 2024Review
- Antibiotic Resistant Biofilms and the Quest for Novel Therapeutic Strategies.Indian journal of microbiology · 2024Review
- Polymer-based antimicrobial strategies for periodontitis.Frontiers in pharmacology · 2024Review
- Treatment of periodontal disease: does drug delivery matter?Frontiers in bioengineering and biotechnology · 2024Article
- Nanoparticles in Periodontitis Therapy: A Review of the Current Situation.International journal of nanomedicine · 2024Review
- Inflammatory macrophages exploited by oral streptococcus increase IL-1B release via NLRP6 inflammasome.Journal of leukocyte biology · 2023Article
- Overview of Antimicrobial Biodegradable Polyester-Based Formulations.International journal of molecular sciences · 2023Review
- Study on Optimizing Novel Antimicrobial Peptides with Bifunctional Activity to Prevent and Treat Peri-Implant Disease.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The interaction of the periodontal pathogen Porphyromonas gingivalis (Pg) with commensal streptococci promotes Pg colonization of the oral cavity. Previously, we demonstrated that a peptide (BAR) derived from Streptococcus gordonii (Sg) potently inhibited adherence of Pg to streptococci and reduced Pg virulence in a mouse model of periodontitis. Thus, BAR may represent a novel therapeutic to control periodontitis by preventing Pg colonization of the oral cavity. However, while BAR inhibited the initial formation of Pg/Sg biofilms, much higher concentrations of peptide were required to disrupt an established Pg/Sg biofilm. To improve the activity of the peptide, poly(lactic-co-glycolic acid) (PLGA) nanoparticles were surface-modified with BAR and shown to more potently disrupt Pg/Sg biofilms relative to an equimolar amount of free peptide. The goal of this work was to determine the in vivo efficacy of BAR-modified NPs (BNPs) and to assess the toxicity of BNPs against human gingival epithelial cells. In vivo efficacy of BNPs was assessed using a murine model of periodontitis by measuring alveolar bone resorption and gingival IL-17 expression as outcomes of Pg-induced inflammation. Infection of mice with Pg and Sg resulted in a significant increase in alveolar bone loss and gingival IL-17 expression over sham-infected animals. Treatment of Pg/Sg infected mice with BNPs reduced bone loss and IL-17 expression almost to the levels of sham-infected mice and to a greater extent than treatment with an equimolar amount of free BAR. The cytotoxicity of the maximum concentration of BNPs and free BAR used in in vitro and in vivo studies (1.3 and 3.4 μM), was evaluated in telomerase immortalized gingival keratinocytes (TIGKs) by measuring cell viability, cell lysis and apoptosis. BNPs were also tested for hemolytic activity against sheep erythrocytes. TIGKs treated with BNPs or free BAR demonstrated >90% viability and no significant lysis or apoptosis relative to untreated cells. In addition, neither BNPs nor free BAR exhibited hemolytic activity. In summary, BNPs were non-toxic within the evaluated concentration range of 1.3-3.4 μM and provided more efficacious protection against Pg-induced inflammation in vivo, highlighting the potential of BNPs as a biocompatible platform for translatable oral biofilm applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.